Flash FinanceUS
After hours S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ROCKET PHARMACEUTICALS, INC. (RCKT)

Rocket Pharmaceuticals adopts severance program and sets executive employment terms

Neutral Impact 3 of 5 shareholder Written later

On August 21, 2026, Rocket Pharmaceuticals adopted a company-wide Severance and Change in Control Program and entered into employment agreements or an amendment with its CEO, General Counsel and Chief Operating Officer. The filing sets out severance levels, including enhanced payments if a termination occurs around a change in control, which define the company's potential payout obligations to these executives.

Key points

  • Program adopted August 21, 2026; CEO receives 15 months base salary without a change in control and 18 months within 12 months after one
  • CEO Gaurav Shah's agreement sets an annual base salary of $674,856 and a 60% target bonus
  • General Counsel Martin Wilson's agreement sets an annual base salary of $547,313 and a 45% target bonus
  • Chief Operating Officer Christopher Stevens' amendment, dated August 21, 2026, amends his July 7, 2025 agreement

The filing

CompanyROCKET PHARMACEUTICALS, INC. (RCKT)
Form8-K, current report
Filed with the SECAug 27, 2026, 4:06 PM ET
Accession number0001140361-26-034689

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.